Research progress in the eradication of Helicobacter pylori with Vanorazan regimen
DU Hongwei1 LI Ting1 ZHANG Aiping1 LIN Yimin2 JIN Zhengxu1▲ ZHANG Dekui2▲#br#
1.Department of Gastroenterology, Lanzhou Second People’s Hospital, Gansu Province, Lanzhou 730030, China;
2.Department of Gastroenterology, the Second Hospital of Lanzhou University, Gansu Province, Lanzhou 730030, China
Abstract：Helicobacter pylori (Hp) is closely related to chronic gastritis, peptic ulcer, and gastric cancer. The eradication rate of Hp with proton pump inhibitor decreased gradually. Vonoprazan (VPZ) is a new potassium ion competitive acid blocker, which can competitively inhibit the combination of K+ and H+-K+-ATPase to inhibit the acid secretion of gastric parietal cells. There have been a number of international reports on the first-line and second-line treatment regimen containing VPZ for eradicating Hp, which are reviewed in this paper.
杜宏伟1 李挺1 张爱萍1 林奕旻2 金正旭1▲ 张德奎2▲. 含沃诺拉赞方案根除幽门螺杆菌研究进展[J]. 中国医药导报, 2022, 19(24): 44-47,76.
DU Hongwei1 LI Ting1 ZHANG Aiping1 LIN Yimin2 JIN Zhengxu1▲ ZHANG Dekui2▲. Research progress in the eradication of Helicobacter pylori with Vanorazan regimen. 中国医药导报, 2022, 19(24): 44-47,76.
[1] Wroblewski LE，Peek RM Jr，Wilson KT. Helicobacter pylori and gastric cancer：factors that modulate disease risk [J]. Clin Microbiol Rev，2010，23（4）：713-739.
[2] Rokkas T，Gisbert JP，Malfertheiner P，et al. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection：A Network Meta-analysis [J]. Gastroenterology，2021，161（2）：495-507.e4.
[3] Shichijo S，Hirata Y，Niikura R，et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori：A multicenter retrospective study in clinical practice [J]. Dig Dis，2016，17（10）：670-675.
[4] Talebi Bezmin Abadi A，Yamaoka Y. Helicobacter pylori therapy and clinical perspective [J]. Glob Antimicrob Resist，2018，14：111-117.
[5] Zhong Z，Zhang Z，Wang J，et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China [J]. Am J Cancer Res，2021，11（10）：5027-5037.
[6] Sue S，Maeda S. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication? [J]. Gut Liver，2021，15（6）：799-810.
[7] Sugimoto M，Hira D，Murata M，et al. Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy [J]. Antibiotics（Basel），2020，9（10）：645.
[8] Sakurai Y，Shiino M，Okamoto H，et al. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan，Amoxicillin，and Clarithromycin or Metronidazole：A Phase 1，Open-Label，Randomized，Crossover Study [J]. Adv Ther，2016，33（9）：1519-1535.
[9] Hunt RH，Scarpignato C. Potassium-Competitive Acid Blockers （P-CABs）：Are They Finally Ready for Prime Time in Acid-Related Disease? [J]. Clin Transl Gastroenterol，2015，6（10）：e119.
[10] Jenkins H，Sakurai Y，Nishimura A，et al. Randomised clinical trial：safety，tolerability，pharmacokinetics and pharmacodynamics of repeated doses of TAK-438（vonoprazan），a novel potassium-competitive acid blocker，in healthy male subjects [J]. Aliment Pharmacol Ther，2015， 41（7）：636-648.
[11] Huh KY，Chung H，Kim YK，et al. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication [J]. Br J Clin Pharmacol，2022，88（1）：138-144.
[12] Kagami T，Sahara S，Ichikawa H，et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole，with reference to CYP2C19 genotype [J]. Aliment Pharmacol Ther，2016，43（10）：1048-1059.
[13] Yamasaki H，Kawaguchi N，Nonaka M，et al. In vitro metabolism of TAK-438，vonoprazan fumarate，a novel potassium-competitive acid blocker [J]. Xenobiotica，2017，47（12）：1027-1034.
[14] Mori H，Suzuki H，Omata F，et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area：a multicenter study with a large number of patients [J]. Therap Adv Gastroenterol，2019， 12：1756284819858511.
[15] Murakami K，Sakurai Y，Shiino M，et al. Vonoprazan，a novel potassium-competitive acid blocker，as a component of first-line and second-line triple therapy for Helicobacter pylori eradication：a phase Ⅲ，randomised，double-blind study [J]. Gut，2016，65（9）：1439-1446.
[16] Suzuki S，Gotoda T，Kusano C，et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy [J]. Am J Gastroenterol，2016，111（7）：949-956.
[17] Shinozaki S，Nomoto H，Kondo Y，et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori [J]. Kaohsiung J Med Sci，2016，32（5）：255-260.
[18] Maruyama M，Tanaka N，Kubota D，et al. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication：A Randomized Controlled Trial [J]. Can J Gastroenterol Hepatol，2017，2017：4385161.
[19] Furuta T，Yamade M，Kagami T，et al. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan，Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori [J]. Digestion，2020，101（6）：743-751.
[20] Mori N，Nishiura Y，Suga D，et al. Second-line triple therapy in failures with vonoprazan -based triple therapy for eradication of Helicobacter pylori [J]. Biomed Rep，2018，9（2）：169-174.
[21] Sakurai K，Suda H，Ido Y，et al. Comparative study：Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy [J]. World J Gastroenterol，2017，23（4）：668-675.
[22] Sue S，Suzuki N，Shibata W，et al. First-Line Helicobacter pylori Eradication with Vonoprazan，Clarithromycin，and Metronidazole in Patients Allergic to Penicillin [J]. Gastroenterol Res Pract，2017，2017：2019802.
[23] Ono S，Kato M，Nakagawa S，et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin [J]. Helicobacter，2017，22（3）：e12374.
[24] Horie R，Handa O，Ando T，et al. Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan [J]. Helicobacter，2020，25（4）：e12698.
[25] Sue S，Kuwashima H，Iwata Y，et al. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin：A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication [J]. Intern Med，2017，56（11）：1277-1285.
[26] Gunaratne AW，Hamblin H，Clancy A，et al. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study [J]. Helicobacter，2021，26（5）：e12830.
京公网安备 11010502046598号